Earnings Ahead

EIGR - Eiger Biopharmaceutical

0.7441 -0.0487 -6.14

  1. Home
  2. Healthcare
  3. EIGR
Eiger Biopharmaceutical

Eiger Biopharmaceutical

About

Profile

Headquarters

Palo Alto, California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

EIGR



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Eiger BioPharmaceuticals GAAP EPS of -$0.57 misses by $0.03, revenue of $2.69M misses by $1.73M
  • Sangamo, Protagonist, and Eiger among biotechs with exposure to Silicon Valley Bank
  • Eiger gains as journal publishes late-stage data for COVID therapy
  • Eiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEO
  • Eiger plunges 70% after late-stage data for chronic hepatitis candidate
  • Eiger BioPharmaceuticals GAAP EPS of -$0.62 misses by $0.10, revenue of $4.02M misses by $0.24M
  • Eiger BioPharmaceuticals Q3 2022 Earnings Preview
  • Citi lists four more value-creating events in biotech for this year
  • Catalyst Watch: Tesla, Netflix, Fisker, TechCrunch Disrupt and Paris Motor Show headline big week
  • Eiger sheds ~20% on abandonment of EUA request for COVID therapy
  • Eiger falls 21% amid uncertainty over regulatory path for COVID-19 therapy
  • Eiger BioPharmaceuticals GAAP EPS of -$0.51 beats by $0.11, revenue of $4.09M misses by $0.99M
  • Eiger BioPharmaceuticals Q2 2022 Earnings Preview
  • European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy
  • Eiger BioPharmaceuticals enter $75M term loan and $5M stock repurchase agreement to bolster cash position
  • EU drug regulator panel recommends approval for Eiger BioPharma's progeria therapy
  • Eiger BioPharmaceuticals GAAP EPS of -$0.64 in-line, revenue of $2.67M misses by $1.38M
  • Eiger BioPharmaceuticals Q1 2022 Earnings Preview
  • Eiger avexitide shows promise in phase 2 trial in children with hyperinsulinism
  • Eiger BioPharmaceuticals appoints Christopher Kurtz as Chief Technical Officer

Earnings History

Date EPS / Forecast Revenue / Forecast
November 4, 2021 -0.5814 / -0.517 3.04M / 2.88M Beat!
August 5, 2021 -0.57 / -0.537 2.1M / 2.08M Beat!
May 6, 2021 0.8953 / -0.0236 3.65M / 13.01M
March 9, 2021 -0.58 / 0.1945 - / 50K
November 5, 2020 -0.4716 / -0.6108 - / -
August 6, 2020 -0.6 / -0.62 - / 0.63M
May 7, 2020 -0.5535 / -0.77 - / 50K
March 13, 2020 -0.635 / -0.39 - / 619.25K
November 7, 2019 -0.69 / -0.72 - / 6.25K
August 8, 2019 -0.75 / -0.71 - / -
May 9, 2019 -0.9 / -0.92 - / -
March 14, 2019 -0.92 / -0.77 - / -
November 9, 2018 -1.2 / -0.77 - / -
August 10, 2018 -0.82 / -0.82 - / -
May 11, 2018 -0.84 / -1.04 - / -
March 21, 2018 - / -1.02 - / -
November 9, 2017 -1.10 / -1.28 - / -
August 9, 2017 -1.33 / -1.28 - / -
May 15, 2017 - / -1.35 - / -
March 27, 2017 -1.53 / -1.42 - / -
November 14, 2016 -1.49 / -1.36 - / -
Date Price Open High Low Vol Change ER
Mar 16 5.690 5.520
5.720
5.320
520.78K 4.40%
Mar 15 5.450 5.250
5.490
5.120
462.71K 3.42%
Mar 14 5.270 5.330
5.840
5.100
534.68K 3.33%
Mar 11 5.100 4.490
5.340
4.410
431.77K 15.38%
Mar 10 4.420 4.500
4.580
4.330
356.53K -3.07%
 
Mar 9 4.560 4.330
4.650
4.280
360.39K 6.79%
Mar 8 4.270 4.100
4.310
4.020
166.98K 4.91%
Mar 7 4.070 4.200
4.270
4.049
182.82K -2.63%
Mar 4 4.180 4.140
4.205
4.120
120.14K -0.24%
Mar 3 4.190 4.210
4.240
4.110
257.17K 0%
Mar 2 4.190 4.160
4.235
4.075
94.80K 1.70%
Mar 1 4.120 4.040
4.200
3.930
171.85K 3%
Feb 28 4.000 4.090
4.180
3.970
165.56K -3.61%
Feb 25 4.150 4.210
4.290
4.080
226.95K -2.35%
Feb 24 4.250 4.080
4.290
3.940
294.92K 4.94%
Feb 23 4.050 4.180
4.180
4.020
144.73K -1.22%
Feb 22 4.100 4.220
4.220
4.000
135.24K -1.68%
Feb 18 4.170 4.240
4.270
4.120
244.68K -2.8%
Feb 17 4.290 4.320
4.433
4.250
113.70K -1.83%